Short Interest in Entero Therapeutics, Inc. (NASDAQ:GRDX) Rises By 470.4%

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 118,986 shares, an increase of 470.4% from the July 30th total of 20,859 shares. Based on an average daily trading volume, of 145,108 shares, the short-interest ratio is currently 0.8 days. Currently, 1.7% of the company’s shares are short sold.

Entero Therapeutics Trading Up 11.2%

Shares of NASDAQ GRDX opened at $4.06 on Wednesday. The stock has a market capitalization of $28.95 million, a PE ratio of -2.16 and a beta of 1.86. Entero Therapeutics has a twelve month low of $1.73 and a twelve month high of $6.93. The stock has a fifty day simple moving average of $3.83 and a 200-day simple moving average of $3.41.

Entero Therapeutics (NASDAQ:GRDX) last posted its quarterly earnings data on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The firm had revenue of $0.04 million during the quarter.

Institutional Investors Weigh In On Entero Therapeutics

An institutional investor recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC purchased a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.